Presentation is loading. Please wait.

Presentation is loading. Please wait.

Collaboration in the Life Sciences November 2011.

Similar presentations


Presentation on theme: "Collaboration in the Life Sciences November 2011."— Presentation transcript:

1 Collaboration in the Life Sciences November 2011

2 Collaboration -> Innovation -> Success 2 A Guiding Principle

3 3 Especially in the Pharmaceutical Industry  No single company has all the necessary skills to develop a pharmaceutical drug  No single country has all the necessary skills to develop a pharmaceutical industry Collaboration is vital, but… …choose your partners with care.

4 4 Commercial Awareness Financial Competence Scientific Excellence What to look for in a good partner? True for academic groups, companies and countries… Supportive Environment

5 5 How does the UK rate?

6 6 Commercial Awareness Financial Competence Scientific Excellence The UK’s Position in the Global Market True for academic groups, companies and countries… Supportive Environment

7 A Key Feature… “Almost half of more than 90,000 research articles published by UK researchers in 2008 had a co-author from another country”.

8 8 …Creating a Success Story  In Europe, the UK biotech sector is developing –40% of all biotechnology projects in pipeline –45% of new biotech drugs in late stage clinical trials  The UK is a ‘super-cluster’ with organisations concentrated around centres of excellence –‘Golden Triangle’ includes Cambridge, Oxford, London  400+ biotechnology companies in the UK –Industry employs nearly 20,000 people directly –Generating revenues of $5 billion Possesses all round expertise in drug discovery and development, in a mature sector

9 The Golden Triangle 9

10 A Dense Environment of Biotechnology  Key bio-cluster hubs of Cambridge, London & Oxford  Europe’s most dense region of life science companies  A highly-connected ecology of life scientists, organisations and companies.  Majority of UK’s life science research undertaken here  Location of vast majority of major Pharma’s EMEA operations

11 Major Pharma in Golden Triangle Abbot Laboratories Actelion Almirral Amgen Astella Pharma AstraZeneca Baxter Healthcare Boston Scientific Bristol Myers Squibb Cambridge Consultants Chugai Pharma Europe Daiichi Sankyo UK Ltd Eisai Europe Elan Pharma Eli Lilly & Co GE Healthcare Philips Roche Sanofi Pasteur MSD Schering Plough Servier Shire Siemens Diagnostics Smiths Medical Stiefel Takeda Global R&D Centre Toyama Europe United Therapeutics UCB Celltech Unilever Vertex Wyeth Genzyme Gilead GlaxoSmithKline Huntleigh Healthcare Ipsen Johnson & Johnson Lundbeck Medtronic Merch Sharp & Dohme Mitsubishi Pharma Europe Napp Pharmaceutical Group Novartis Olympus Ono Pharma OSI Pfizer

12 Future developments planned in the London - Cambridge Corridor London Bio and finance cluster BioPark Cluster, Welwyn Garden City GSK Science Park, Stevenage Cambridge BioCluster UKCMRI planned for 2016 £500M World leading research institute GSK + Govt backed £170M science park on GSK campus for 2013 Development of Cambridge Biomedical Campus Oxford Science Park Ongoing Expansion of Oxford Science Park

13 13 …and financial commitment Chancellor George Osborne has said the Government will protect the £4.6 billion science budget, which will see £220 million investment in the UK Centre for Medical Research and Innovation at St Pancras, London. NHS funding will increase from £104bn to £114bn over the next four years, the chancellor of the exchequer has confirmed.

14 How can you capitalise on this Success Story? 14

15 15 How Technology Specialists Help Overseas Companies Overseas Overseas UKTI Groups Science & Innovation Networks In the UK UKTI Sector & Business Groups Investment Team Regional Organisations Activities Identify and assess R&D activities Analyse business opportunities Promote the UK Provide Detailed scientific information Access to technology and technology networks Access to specific oganisions Overseas companies UK Technology Capabilities Technology Specialists

16 16 Conclusions  Success in the BioPharma industry will require new models of collaboration.  The UK has a world-class life science industry, geared to international collaboration  The ‘Golden Triangle’ is home to most of the UK’s BioPharma industry, and is continuing to thrive.  UKTI can provide practical and dedicated support to companies wishing to invest in the UK.  Success in the BioPharma industry will require new models of collaboration.  The UK has a world-class life science industry, geared to international collaboration  The ‘Golden Triangle’ is home to most of the UK’s BioPharma industry, and is continuing to thrive.  UKTI can provide practical and dedicated support to companies wishing to invest in the UK.

17 Thank You

18 Contact Details Nigel Whittle PhD MBA Technology Specialist | Life Sciences UK Trade & Investment 1 Victoria Street London SW1E 6SW M: +44 (0) T: +44 (0) E: W: UK Trade & Investment is the Government organisation that helps UK based companies succeed in international markets. It also assists overseas companies to bring high quality investment to the UK's vibrant economy.


Download ppt "Collaboration in the Life Sciences November 2011."

Similar presentations


Ads by Google